Nobiletin Inhibits Epithelial–Mesenchymal Transition in A549 Cells, a Model of Early Lung Cancer Related to Pulmonary Nodules, Through Wnt/β-Catenin Pathway Inactivation
Acta Poloniae Pharmaceutica - Drug Research · 20.07.2026 · 84 (2) · 177-184
DOI: 10.32383/appdr/224959 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Poloniae Pharmaceutica - Drug Research, online erschienen am 20.07.2026. Verfasst von Lide Wang und 4 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Malignant transformation of pulmonary nodules represents a critical window for early lung cancer intervention. Although epithelial–mesenchymal transition (EMT) driven by Wnt/β-catenin signaling promotes this process, whether Nobiletin, a major polymethoxylated flavonoid derived from Citri Reticulatae Pericarpium, can block EMT in early-stage lung cancer remains unclear.
Objective
This study aimed to investigate the effects of Nobiletin on EMT-associated phenotypes in A549 cells, an in vitro model relevant to early lung adenocarcinoma and pulmonary nodule malignant transformation, and to explore whether these effects involve Wnt/β-catenin pathway inactivation.
Methods
A549 cells were treated with Nobiletin at non-cytotoxic concentrations. Cell viability was assessed using a CCK-8 assay. Cell migration was evaluated by wound healing and Transwell assays. Morphological changes were observed under phase-contrast microscopy. EMT markers, including E-cadherin and Vimentin, and β-catenin subcellular localization were examined by immunofluorescence staining.
Results
Nobiletin did not significantly affect cell viability at the tested concentrations. Functional assays showed that Nobiletin markedly inhibited A549 cell migration. Morphological observation revealed a shift from a mesenchymal-like phenotype to a more epithelial-like phenotype. Immunofluorescence analysis showed increased E-cadherin expression, decreased Vimentin expression, and reduced nuclear accumulation of β-catenin after Nobiletin treatment.
Conclusion
Nobiletin suppresses EMT-associated phenotypes in A549 cells, potentially through inactivation of the Wnt/β-catenin signaling pathway. These findings provide preliminary experimental evidence supporting the potential role of Nobiletin in preventing malignant progression of pulmonary nodules.
Zitieren
APA
Wang, L., Cao, J., Tang, T., Ren, W., & Chen, L. (2026). Nobiletin Inhibits Epithelial–Mesenchymal Transition in A549 Cells, a Model of Early Lung Cancer Related to Pulmonary Nodules, Through Wnt/β-Catenin Pathway Inactivation. Acta Poloniae Pharmaceutica - Drug Research, 84(2), 177-184. https://doi.org/10.32383/appdr/224959
Vancouver
Wang L, Cao J, Tang T, Ren W, Chen L. Nobiletin Inhibits Epithelial–Mesenchymal Transition in A549 Cells, a Model of Early Lung Cancer Related to Pulmonary Nodules, Through Wnt/β-Catenin Pathway Inactivation. Acta Poloniae Pharmaceutica - Drug Research. 2026;84(2):177-184. doi:10.32383/appdr/224959
BibTeX
@article{Wang2026,
author = {Wang, Lide and Cao, Jianguang and Tang, Tian and Ren, Weihao and Chen, Lei},
title = {Nobiletin Inhibits Epithelial–Mesenchymal Transition in A549 Cells, a Model of Early Lung Cancer Related to Pulmonary Nodules, Through Wnt/β-Catenin Pathway Inactivation},
journal = {Acta Poloniae Pharmaceutica - Drug Research},
year = {2026},
volume = {84},
number = {2},
pages = {177--184},
doi = {10.32383/appdr/224959}
}
EUVIMED